Modulating plasmacytoid dendritic cells to reduce inflammation
ANB101 targets BDCA2 on pDCs — potently inhibiting interferon secretion and downstream immune activation at a central upstream driver of autoimmune and inflammatory disease.
ANB101 is a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
By engaging BDCA2, a molecule expressed primarily on pDCs, ANB101 aims to potently inhibit interferon secretion and downstream immune activation, addressing a central driver of autoimmune and inflammatory disease
Why ANB101 is a promising approach for autoimmune and inflammatory diseases
pDCs play a pivotal role in bridging innate and adaptive immunity. When activated, they:
- Secrete Type I interferons at levels up to 1,000× higher than other immune cells
- Present antigens to the adaptive immune system
- Amplify inflammatory cascades that sustain chronic disease
pDCs accumulate in inflamed tissues across rheumatologic and other immune-mediated diseases. Prior BDCA2-modulating approaches have demonstrated mechanistic proof-of-concept in lupus, underscoring the therapeutic potential of this pathway.
Robert working in the First Tracks Lab
How ANB101 works
Inhibition of Type I interferon secretion
- ANB101 profoundly reduces interferon production — a key amplifier of autoimmune inflammation
- Lower interferon levels help reduce downstream immune activation and inflammatory cytokine release
Data suggest ANB101’s more potent antibody results in:
- Longer half-life compared to litifilimab
- Deeper and more durable PD effect on pDC depletion
Together, these effects position ANB101 as a promising upstream modulator of immune activity across multiple autoimmune and inflammatory diseases.
For the latest on our clinical development